Výsledky vyhledávání

Data from The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

Autor: Keunchil Park, Myung-Ju Ahn, Sai-Hong Ou, Jin Seok Ahn, Amir Abolhoda, ZhengYun Cui, Jeonghun Ko, Youngwook Kim

Molecular target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCL

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8ebe7bc9193ea08d6931af436a17f47
https://doi.org/10.1158/1535-7163.c.6535806

Zobrazit plný text záznamu

Supplementary Figures 1-4 from The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

Autor: Keunchil Park, Myung-Ju Ahn, Sai-Hong Ou, Jin Seok Ahn, Amir Abolhoda, ZhengYun Cui, Jeonghun Ko, Youngwook Kim

PDF file - 1.9MB

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51942b961d13b2c01af8afcd86a7cd22
https://doi.org/10.1158/1535-7163.22498143

Zobrazit plný text záznamu

Abstract 3608: PTEN mutation associated with EGFR TKI de novo resistance

Autor: Myung-Ju Ahn, Jeonghun Ko, Young-Wook Kim, Zheng Yun Cui, Keunchil Park

Publikováno v: Cancer Research. 70:3608-3608

Epidermal growth factor receptor (EGFR) is overexpressed in 60-80% of non-small cell lung cancer patients. Recent identification that EGFR-tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib, has marked therapeutic effect in a subs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8cca6abb27d789127c40c8a11a01eb86
https://doi.org/10.1158/1538-7445.am10-3608

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání